deCODE genetics, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for deCODE genetics, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

deCODE genetics, Inc.. The Group's principal activity is to develop and market products to improve the treatment, diagnosis and prevention of common diseases. It applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. Its lead drug development programs include: DG041 for the prevention of arterial thrombosis. The products include deCODE T2TM, deCODE AFTM, deCODE MITM, deCODEmeTM, deCODEProstateCancerTM, deCODE GlaucomaTM, deCODE BreastCancerTM. Other DNA-based risk diagnostic tests currently in development include: melanoma, basal cell cancer, bladder cancer and lung cancer.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report